Mary Kinsey Counselor Medicare: Not Enrolled in Medicare Practice Location: 26813 Park Ln, Woodhaven, MI 48183 Phone: 734-777-6375 |
News Archive
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
Scientists report that adult stem cells isolated from humans with muscular dystrophy can be genetically corrected and used to induce functional improvement when transplanted into a mouse model of the disease.
Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.
Columbia Laboratories, Inc. announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014.
A compound discovered and developed by a team of Georgetown Lombardi Comprehensive Cancer Center researchers that halts cancer in animals with Ewing sarcoma and prostate cancer appears to work against some forms of leukemia, too.
› Verified 3 days ago